CABR · Caring Brands, Inc. · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-23 | John Brian |
Director |
Other↓
Filing footnotes — Common Stock (Direct)
Represents redemption of 150,000 shares of common stock of the Issuer at approximately $1.00 per share pursuant to that certain Share Redemption Agreement dated July, 10, 2026, by and between the Issuer and BK Investments LLC, an entity owned by the Reporting Person, the Issuer's Chairman and Interim Chief Financial Officer. |
Common Stock
|
150,000 |
| 2026-03-27 | John Brian |
Director |
Other↓
Filing footnotes — Common Stock (Direct)
Represents redemption of 1,250,000 shares of common stock of the Issuer at approximately $1.00 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026. |
Common Stock
|
1,250,000 |
| 2026-03-27 | WILSON GLYNN |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Common Stock (Direct)
Represents redemption of 1,500,000 shares of common stock of the Issuer at approximately $0.50 per share pursuant to that certain Share Redemption Agreement signed by the Reporting Person and the Issuer on March 19, 2026. The number of shares of common stock beneficially owned following the reported transaction includes Dr. Wilson's ownership of (i) 126,720 restricted stock units of common stock of the Issuer of which zero have vested, (ii) 45,872 restricted stock units of common stock of the Issuer of which zero have vested, and (iii) 500,000 shares of common stock. |
Common Stock
|
1,500,000 |
| 2025-12-11 | WILSON GLYNN |
Director, Chief Executive Officer |
Award↓
Filing footnotes — Common Stock (Direct)
On December 11, 2025, on recommendation of the Compensation Committee of the Board of the Issuer, the Board approved the issuance of 45,872 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on December 11, 2026. The vesting of shares is subject to Dr. Wilson's continued service with the Company. The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock. |
Common Stock
|
45,872 |
| 2025-12-11 | Moore Tyler Thomas |
Chief Financial Officer |
Award↓
Filing footnotes — Common Stock (Direct)
On December 11, 2025, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Issuer, the Board approved the issuance of 270,000 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on June 11, 2026. The vesting of shares is subject to Mr. Moore's continued services with the Company. |
Common Stock
|
270,000 |
| 2025-12-11 | Galeta Christopher Matthew |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan. The options vested immediately on December 11, 2025. |
Stock Option (Right to Buy)
|
25,000 |
| 2025-12-11 | Melton Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan. The options vested immediately on December 11, 2025. |
Stock Option (Right to Buy)
|
25,000 |
| 2025-12-11 | Alila Hector W |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved this option grant under the Company's equity incentive plan. The options vested immediately on December 11, 2025. |
Stock Option (Right to Buy)
|
25,000 |
| 2025-12-11 | Moore Tyler Thomas |
Chief Financial Officer |
Award↓
Filing footnotes — Common Stock (Direct)
On December 11, 2025, on recommendation of the Compensation Committee of the Board of the Issuer, the Board approved the issuance of 30,000 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on December 11, 2026. The vesting of shares is subject to Mr. Moore's continued service with the Company. |
Common Stock
|
30,000 |
| 2025-12-11 | John Brian |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 11, 2025, at the recommendation of the Issuer's Compensation Committee, the Issuer's Board of Directors approved the grant of 100,000 options, under the Company's equity incentive plan. The options shall fully vest on June 11, 2026. Vesting of options is subject to the Reporting Person's continued services with the Issuer. Does not include the 2,000,000 shares of common Stock of the Issuer owned by the Reporting Person. |
Stock Option (Right to Buy)
|
100,000 |
| 2025-12-11 | WILSON GLYNN |
Director, Chief Executive Officer |
Award↓
Filing footnotes — Common Stock (Direct)
On December 11, 2025, on recommendation of the Compensation Committee of the Board of Directors ("Board") of the Issuer, the Board approved the issuance of 126,720 restricted stock units of common stock of the Issuer, under its equity incentive plan. The RSU shares will fully vest on June 11, 2026. The vesting of shares is subject to Dr. Wilson's continued services with the Company. The number of shares of common stock beneficially owned following the reported transactions includes Dr. Wilson's ownership of 2,000,000 shares of common stock. |
Common Stock
|
126,720 |